3,4-dihydroxyphenylacetic acid has been researched along with oxazolidin-2-one in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Da Prada, M; Keller, HH; Kettler, R | 1 |
Fuller, RW; Hemrick-Luecke, SK | 1 |
Waldmeier, PC | 1 |
3 other study(ies) available for 3,4-dihydroxyphenylacetic acid and oxazolidin-2-one
Article | Year |
---|---|
[Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents; Benzamides; Blood Pressure; Heart Rate; Moclobemide; Monoamine Oxidase Inhibitors; Oxazoles; Oxazolidinones; Piperidines; Rats; Serotonin; Structure-Activity Relationship; Tranylcypromine | 1989 |
Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Alkaloids; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Harmaline; Homovanillic Acid; Male; Mice; Monoamine Oxidase Inhibitors; Oxazoles; Oxazolidinones; Oxidation-Reduction; Pyridines | 1985 |
On the reversibility of reversible MAO inhibitors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzamides; Brain; Clorgyline; Dopamine; Female; Homovanillic Acid; Kinetics; Liver; Moclobemide; Monoamine Oxidase Inhibitors; Oxazoles; Oxazolidinones; Phenethylamines; Piperidines; Rats; Rats, Inbred Strains; Serotonin | 1985 |